Alexander C. Herzick

Prior to joining THP, Alex most recently worked in Business Development in the Oncology/Multiple Sclerosis Group at Genzyme Corporation. At Genzyme, he structured licensing and M&A transactions in the biotechnology and pharmaceuticals space. He has also worked as a Portfolio Manager at BlueMountain Capital Management and as an Analyst in Investment Banking at Bank of America Securities. Alex represents THP on the boards of Argonaut, Carterra, Dynex and Teknova (NASDAQ:TKNO). He is a board observer at Agena Bioscience (acquired by Mesa Laboratories). Alex holds an MBA with honors from Northwestern University’s Kellogg School of Management and a Bachelor of Science in Economics from Duke University.